AKAlastair C. Keen

Alastair C. Keen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alastair C. Keen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hox-C12 coordinates β 2 -adrenoceptor coupling to a cAMP/calcium feedforward loop to drive invasion in triple-negative breast cancer

    by Terrance Lam, Bailey Cardwell, Bonan Liu, Cheng Peng, Mia Spark, Sandra Sursock, Cameron J. Nowell, Andrew M. Ellisdon, Aeson Chang, Alastair C. Keen, et al.

    Noradrenaline released from sympathetic neurons accelerates cancer metastasis by activating β 2 -adrenergic receptors (β 2 -adrenoceptors) on tumor cells to promote invasion. We previously showed that the β 2 -adrenoceptor promotes invasive behavior in a metastatic triple-negative breast cancer (TNBC) cell line by activating a cAMP- and calcium-mediated feedforward loop. Here, we found this mechanism in most TNBC lines that have an active β 2 -adrenoceptor. Integrated analysis of transcriptomic datasets revealed HOXC12 , which encodes a developmental homeobox transcription factor, as the most discriminating gene separating cell lines with the feedforward loop and those without it. The high expression of HOXC12 did not correlate with transcriptional changes in integral proteins associated with cAMP or calcium signaling, and immunostaining showed cytosolic localization of Hox-C12, suggesting that it played a nontranscriptional role. Knocking out HOXC12 prevented β 2 -adrenoceptor–mediated calcium signaling and invasion in cultured TNBC cells. In basal breast cancers, HOXC12 expression in tumors negatively correlated with overall and disease-free survival in patients. These findings identify a key mediator, Hox-C12, in the coordination of invasion driven by cAMP and calcium signaling in β 2 -adrenoceptor–responsive TNBC cells.


  • Open Access

    Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine D2 Receptor

    by Herman D. Lim, Damian Bartuzi, Alastair C Keen, Caroline Rauffenbart, Jacqueline Glenn, Steven J. Charlton, Silvia Lovera, Zara A. Sands, Ali Ates, Martyn Wood, et al.

    Recently, the first small-molecule positive allosteric modulators (PAMs) of the dopamine D2 receptor (D2R) were identified. The more potent PAM potentiated the effects of D2R signaling in vitro and in an in vivo model predictive of anti-Parkinson's efficacy. We reveal, based on the results of our site-directed mutagenesis and molecular dynamics experiments, that this scaffold binds to a hitherto unexploited lipid-exposed extrahelical allosteric site in the D2R that lies in a cleft toward the intracellular aspect of the D2R defined by residues in transmembrane domains 1 and 7 and helix 8. By binding to this site, the PAM acts to potentiate the binding affinity of efficacious agonists, such as dopamine. Our simulations suggest that the PAM achieves this effect by stabilizing an active-like conformation of the receptor, similar to the G protein-bound state with TM5 and the tyrosine toggle switch playing the major role.


  • Open Access

    LYCHOS is a human hybrid of a plant-like PIN transporter and a GPCR

    by Charles Bayly-Jones, Christopher J. Lupton, Alastair C. Keen, Shuqi Dong, Chantel Mastos, Wentong Luo, Chunyi Qian, Gareth D. Jones, Hari Venugopal, Yong-Gang Chang, et al.

    Lysosomes have crucial roles in regulating eukaryotic metabolism and cell growth by acting as signalling platforms to sense and respond to changes in nutrient and energy availability1. LYCHOS (GPR155) is a lysosomal transmembrane protein that functions as a cholesterol sensor, facilitating the cholesterol-dependent activation of the master protein kinase mechanistic target of rapamycin complex 1 (mTORC1)2. However, the structural basis of LYCHOS assembly and activity remains unclear. Here we determine several high-resolution cryo-electron microscopy structures of human LYCHOS, revealing a homodimeric transmembrane assembly of a transporter-like domain fused to a G-protein-coupled receptor (GPCR) domain. The class B2-like GPCR domain is captured in the apo state and packs against the surface of the transporter-like domain, providing an unusual example of a GPCR as a domain in a larger transmembrane assembly. Cholesterol sensing is mediated by a conserved cholesterol-binding motif, positioned between the GPCR and transporter domains. We reveal that the LYCHOS transporter-like domain is an orthologue of the plant PIN-FORMED (PIN) auxin transporter family, and has greater structural similarity to plant auxin transporters than to known human transporters. Activity assays support a model in which the LYCHOS transporter and GPCR domains coordinate to sense cholesterol and regulate mTORC1 activation.


  • Open Access

    The application of targeted protein degradation technologies to G protein‐coupled receptors

    by Alastair C. Keen, Manuela Jörg, Michelle L. Halls

    The ubiquitin‐proteasome system is one of the major pathways for the degradation of cellular proteins. In recent years, methods have been developed to exploit the ubiquitin‐proteasome system to artificially degrade target proteins. Targeted protein degraders are extremely useful as biological tools for discovery research. They have also been developed as novel therapeutics with several targeted protein degraders currently in clinical trials. However, almost all targeted protein degrader technologies have been developed for cytosolic proteins. The G protein‐coupled receptor (GPCR) superfamily is one of the most important classes of drug targets, yet only limited examples of GPCR degradation exist. Here, we review these examples and provide a perspective on the different strategies that have been used to apply targeted protein degradation to GPCRs. We also discuss whether alternative approaches that have been used to degrade other integral membrane proteins could be applied to the degradation of GPCRs.LINKED ARTICLES: This article is part of a themed issue Therapeutic Targeting of G Protein‐Coupled Receptors: hot topics from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2021 Virtual Annual Scientific Meeting. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc


  • Open Access

    Structure of the metastatic factor P-Rex1 reveals a two-layered autoinhibitory mechanism

    by Yong-Gang Chang, Christopher J. Lupton, Charles Bayly-Jones, Alastair C. Keen, Laura D’aNdrea, Christina M. Lucato, Joel R. Steele, Hari Venugopal, Ralf B. Schittenhelm, James C. Whisstock, et al.

    P-Rex (PI(3,4,5)P3-dependent Rac exchanger) guanine nucleotide exchange factors potently activate Rho GTPases. P-Rex guanine nucleotide exchange factors are autoinhibited, synergistically activated by Gβγ and PI(3,4,5)P3 binding and dysregulated in cancer. Here, we use X-ray crystallography, cryogenic electron microscopy and crosslinking mass spectrometry to determine the structural basis of human P-Rex1 autoinhibition. P-Rex1 has a bipartite structure of N- and C-terminal modules connected by a C-terminal four-helix bundle that binds the N-terminal Pleckstrin homology (PH) domain. In the N-terminal module, the Dbl homology (DH) domain catalytic surface is occluded by the compact arrangement of the DH-PH-DEP1 domains. Structural analysis reveals a remarkable conformational transition to release autoinhibition, requiring a 126° opening of the DH domain hinge helix. The off-axis position of Gβγ and PI(3,4,5)P3 binding sites further suggests a counter-rotation of the P-Rex1 halves by 90° facilitates PH domain uncoupling from the four-helix bundle, releasing the autoinhibited DH domain to drive Rho GTPase signaling.


  • Open Access

    OZITX, a pertussis toxin-like protein for occluding inhibitory G protein signalling including Gαz

    by Alastair C. Keen, Maria Hauge Pedersen, Laura Lemel, Daniel J. Scott, Meritxell Canals, Dene R. Littler, Travis Beddoe, Yuki Ono, Lei Shi, Asuka Inoue, et al.

    Heterotrimeric G proteins are the main signalling effectors for G protein-coupled receptors. Understanding the distinct functions of different G proteins is key to understanding how their signalling modulates physiological responses. Pertussis toxin, a bacterial AB5 toxin, inhibits Gαi/o G proteins and has proven useful for interrogating inhibitory G protein signalling. Pertussis toxin, however, does not inhibit one member of the inhibitory G protein family, Gαz. The role of Gαz signalling has been neglected largely due to a lack of inhibitors. Recently, the identification of another Pertussis-like AB5 toxin was described. Here we show that this toxin, that we call OZITX, specifically inhibits Gαi/o and Gαz G proteins and that expression of the catalytic S1 subunit is sufficient for this inhibition. We identify mutations that render Gα subunits insensitive to the toxin that, in combination with the toxin, can be used to interrogate the signalling of each inhibitory Gα G protein.


  • Optimization and 13CH3 methionine labeling of a signaling competent neurotensin receptor 1 variant for NMR studies

    by Fabian Bumbak, Alastair C. Keen, Natalie J. Gunn, Paul R. Gooley, Ross A.D. Bathgate, Daniel J. Scott